追加説明:
United States late-stage biopharmaceutical company founded in Cupertino, California and acquired by Bausch Health in September 2025, developing larsucosterol - an epigenetic modulator with Breakthrough Therapy Designation entering Phase III for alcohol-associated hepatitis - alongside its SABER and ORADUR sustained release drug delivery platforms.
評価とコメントを残す